Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ovarian cancer prognosis marker combination and application thereof

A technology of diagnostic markers and markers, applied in the field of clinical analysis

Pending Publication Date: 2020-02-28
ZHEJIANG CANCER HOSPITAL
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In the prior art, there is no research on the relationship between UTP23 and its downstream molecule GDF15 and drug resistance in ovarian cancer. The present invention will find and verify the relationship between the above-mentioned molecules and ovarian cancer drug resistance and prognosis through in vitro and actual case experiments. Help with clinical treatment of ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ovarian cancer prognosis marker combination and application thereof
  • Ovarian cancer prognosis marker combination and application thereof
  • Ovarian cancer prognosis marker combination and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 sample preparation

[0026] 1. Sample collection

[0027] In this study, a total of 79 patients diagnosed with epithelial ovarian cancer in Zhejiang Cancer Hospital from May 2010 to November 2013 were collected. All patients received standard treatment: primary tumor cytoreductive surgery or primary staging Surgery plus 6-8 courses of first-line chemotherapy after surgery (platinum combined with paclitaxel), divided according to tumor tissue types: 1. Serous adenocarcinoma; 2. Mucinous adenocarcinoma; 3. Endometrioid adenocarcinoma; 4. Clear cell 5. Unclassified adenocarcinoma; 6. Transitional cell carcinoma; 7. Two or more mixed carcinomas. (See Table 3.1.1). The clinicopathological data of each patient were carefully collected, and the patients were followed up by telephone after the treatment. The last follow-up time was September 2018, and the patients were followed up for 58-100 months, of which 7 patients were lost to follow-up.

[0028] 2. Defini...

Embodiment 3

[0059] Example 3 The ratio of expression of UTP23 and its potential downstream molecule GDF15 is associated with chemotherapy resistance and poor prognosis

[0060] According to the above definition, the expression of UTP23 and the downstream molecule GDF15 in the cases were subjected to immunohistochemical experiments and scored after statistics. The specific results are shown in Table 2

[0061] Table 2 Correlation between UTP23 / GDF15 expression ratio and clinicopathological parameters

[0062]

[0063]

[0064] UTP23 is mainly expressed in the nucleus and / or cytoplasm of ovarian cancer cells, while GDF15 is mainly expressed in the cytoplasm of ovarian cancer cells, and the coloring is brown or brown ( figure 1a). In paclitaxel-resistant ovarian cancer patients, the low ratio of UTP23 to GDF15 was 78.6% (11 / 14), which was significantly higher than paclitaxel-sensitive ovarian cancer patients, whose low ratio accounted for 38.5% (25 / 65). The ratio was statistically si...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an ovarian cancer drug-resistance marker UTP23, an expression ratio of an existing gene GDF15 and related prognosis of ovarian cancers. Particularly, when the ratio is low, anovarian cancer case shows poor prognosis according to prognostic indicators such as chemotherapy sensitivity, drug resistance, satisfactory cytoreductive surgery, progression free survival and overallsurvival. When the ratio is high, an ovarian cancer patient shows good prognosis, namely, clinical therapy of the ovarian cancers includes chemotherapy and surgical therapy to provide prognosis prompt.

Description

technical field [0001] The present invention belongs to the field of molecular biology, specifically relates to the field of diagnosis / grading / staging and prognosis of cancer, more specifically, the present invention relates to the field of ovarian cancer. The present invention also relates to the fields of ovarian cancer diagnosis, grading, staging and prognosis including the expression of biomarkers, and also provides related analytical reagents, diagnostic models, test kits and clinical analysis. Background technique [0002] Ovarian cancer is the gynecological tumor with the highest mortality rate among women in my country. According to the China Cancer Annual Report, there were about 52,100 new patients in 2015, and about 22,500 people died of ovarian cancer in the same year. With the aging population in my country, the incidence of ovarian cancer is increasing year by year, and the age of onset tends to be younger. Globally, the incidence of ovarian cancer ranks third...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/68G01N33/577G01N33/574
CPCC12Q1/6886G01N33/68G01N33/577G01N33/57449G01N33/57496G01N33/57484C12Q2600/118C12Q2600/158C12Q2600/106
Inventor 傅志勤鲁超施亮杨悦陈雅卿张平朱笕青程向东
Owner ZHEJIANG CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com